DSAM Partners (London) Ltd - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.

Quarter-by-quarter ownership
DSAM Partners (London) Ltd ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q2 2021$4,900,000
-1.1%
80,3840.0%0.82%
-10.3%
Q1 2021$4,952,000
-30.3%
80,384
-19.6%
0.92%
+10.3%
Q4 2020$7,107,00099,9370.83%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2021
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$373,797,00067.28%
Darwin Global Management, Ltd. 2,090,149$128,753,00025.21%
Affinity Asset Advisors, LLC 577,500$35,574,00012.08%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$1,913,356,0009.64%
Perceptive Advisors 7,756,928$477,827,0006.04%
Opaleye Management Inc. 583,767$35,960,0005.28%
MIZUHO MARKETS AMERICAS LLC 171,923$10,590,0004.93%
VIKING GLOBAL INVESTORS LP 26,620,991$1,639,853,0004.88%
Fernwood Investment Management, LLC 151,085$9,307,0003.42%
HHLR ADVISORS, LTD. 5,362,014$330,300,0003.26%
View complete list of BRIDGEBIO PHARMA INC shareholders